743

Patient (pt) reported outcomes (PROs) in SPARTAN, a phase 3, double-blind, randomized study of apalutamide (APA) plus androgen deprivation therapy (ADT) vs placebo (PBO) plus ADT in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)

By: Saad F. 1, Small E. 2, Hadaschik B. 3, Graff J. 4, Mainwaring P. 5, McQuarrie K. 6, Li S. 7, Lawson J. 8, Lopez-Gitlitz A. 9, Smith M. 10

1University of Montréal Health Center, Dept. of Urology, Montréal, Canada, 2Helen Diller Family Comprehensive Cancer Center, Dept. of Medicine, San Francisco, United States of America, 3University of Duisburg-Essen, Dept. of Urology, Essen, Germany, 4Oregon Health & Science University, Knight Cancer Institute, Portland, United States of America, 5Canossa Private Hospital, Medical Oncology, Brisbane, Australia, 6Janssen Global Services, Dept. of Urology, Horsham, United States of America, 7Janssen Research & Development, Clinical Biostats, Spring House, United States of America, 8Janssen Research & Development, Dept. of Oncology, Raritan, United States of America, 9Janssen Research & Development, Clinical Oncology, Los Angeles, United States of America, 10Massachusetts General Hospital Cancer Center, Dept. of Hematology, Boston, United States of America

744

Phase 3 study of intermittent monotherapy versus continuous combined androgen deprivation

By: Calais Da Silva Junior F. 1, Calais Da Silva Senior F. 1, Gonçalves F. 2, Kliment J. 3, Santos A. 4, Pastidis S. 5, Queimadelos A. 6, Robertson C. 7

1CHLC-Hospital S.José, Dept. of Urology, Lisbon, Portugal, 2CUIMED A Saint Michal Hospital, Dept. of Urology, Bratislava, Slovakia, 3Jessenius Schooll of Medicine, Dept. of Urology, Martin, Slovakia, 4Hospital de Braga, Dept. of Urology, Braga, Portugal, 5Amalia Fleming Hospital, Dept. of Urology, Athens, Greece, 6Policlinica La Rosaleda, Dept. of Urology, Santiago Compostela, Spain, 7University of Strathclyde, Dept. of Urology, Glasgow, United Kingdom

745

Decline in serum androgens and survival in metastatic castration resistant prostate cancer (MCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (alliance)
By: Ryan C., Dutta S., Kelly W., Russell C., Small E., Taplin M-E., Halabi S.
1University of California San Francisco, Dept. of Medicine and Urology, San Francisco, United States of America, 2Duke University Medical Center, Dept. of Biostatistics and Bioinformatics, Durham, United States of America, 3Thomas Jefferson University, Dept. of Medicine, Philadelphia, United States of America, 4University of California San Francisco, Dept. of Medicine, San Francisco, United States of America, 5Memorial Sloan Kettering Cancer Center, Dept. of Medicine, New York, United States of America, 6Harvard Medical School, Dana-Farber Cancer Institute, Boston, United States of America

746 Radical prostatectomy with combined chemo-hormonal therapy in prostate cancer patients with lymph node metastases

By: Nyushko K.M., Alekseev B., Ustinova T., Paichadze A., Kaprin A.
1P.A. Herzen Moscow Oncological Research Institute, Dept. of Urology, Moscow, Russia, 2P.A. Herzen Moscow Oncological Research Institute, Dept. of Oncology, Moscow, Russia, 3P.A. Herzen Moscow Oncological Research Institute, Dept. of Chemotherapy, Moscow, Russia

747 Androgen deprivation therapy for prostate cancer and risk of dementia

1Höglandssjukhuset, Dept. of Urology, Eksjö, Sweden, 2Uppsala University Hospital, Regional Cancer Centre, Uppsala, Sweden, 3King’s College London, School of Cancer and Pharmaceutical Sciences, Dept. of Translational Oncology & Urology Research (TOUR), London, United Kingdom, 4University of Gothenburg, Sahlgrenska Academy, Dept. of Urology, Gothenburg, Sweden, 5Karolinska Institute, Dept. of Clinical Geriatrics - NVS, Stockholm, Sweden, 6Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, 7Karolinska Institute, Dept. of Clinical Science Intervention and Technology (CLINTEC), Stockholm, Sweden

748 Four vs ten months of induction ADT for intermittent therapy (the FIT trial): A prospective CURC randomized trial

By: Klotz L., Loblaw A., Siemens R., Ouellette P., Kapoor A., Saad F.
1Sunnybrook HSC, University of Toronto, Dept. of Urology, Toronto, Canada, 2Sunnybrook HSC, University of Toronto, Dept. of Radiation Oncology, Toronto, Canada, 3Queen's University, Dept. of Urology, Kingston, Canada, 4Granby Hospital, Dept. of Urology, Granby, Canada, 5McMaster University, Dept. of Urology, Hamilton, Canada, 6Universite de Montreal, Dept. of Urology, Montreal, Canada

749 Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer

750 Non-alcoholic fatty liver disease in men undergoing androgen deprivation therapy for prostate cancer

By: Gild P. 1, Cole A. 2, Von Landenberg N. 3, Sun M. 4, Mucci L. 5, Chun F. 6, Nguyen P. 7, Kibel A. 8, Trinh Q-D. 2

1University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 2Brigham And Women's Hospital, Harvard Medical School, Division of Urological Surgery and Center for Surgery and Public Health, Boston, United States of America, 3Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology, Bochum, United States of America, 4Dana Farber Cancer Institute, Harvard Medical School, Dept. of Medical Oncology, Boston, United States of America, 5Harvard T.H. Chan School of Public Health, Dept. of Epidemiology, Boston, United States of America, 6University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, 7Dana-Farber Cancer Institute, Harvard Medical School, Dept. of Radiation Oncology, Boston, United States of America, 8Brigham And Women's Hospital, Harvard Medical School, Division of Urological Surgery, Boston, United States of America

751 Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: A multi-center analysis

By: Koo K.C. 1, Lee J.S. 2, Kim J.W. 1, Kang S.K. 1, Lee K.S. 1, Kim D.K. 1, Ha Y.S. 1, Cho K.S. 1, Rha K.H. 2, Hong S.J. 2, Chung B.H. 1

1Yonsei University College of Medicine, Gangnam Severance Hospital, Dept. of Urology, Seoul, Korea, South, 2Yonsei University College of Medicine, Shinchon Severance Hospital, Dept. of Urology, Seoul, Korea, South

752 New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study

By: Jhan J.H., Yeh H.C., Chang Y.H., Guu S.J., Wu W.J., Chou Y.H., Li C.C.

Kaohsiung Medical University, Dept. of Urology, Kaohsiung, Taiwan

753 Assessment of androgen deprivation therapy efficacy is more reliable with luteinizing-hormone measurement: Need to change the concept?

By: Cuadras M. 1, Miret E. 1, López R. 1, Comas I. 2, Ferrer R. 2, Regis L. 1, Celma A. 1, Planas J. 1, Placer J. 1, Morote J. 1

1Vall d'Hebron University Hospital, Dept. of Urology, Barcelona, Spain, 2Vall d'Hebron University Hospital, Dept. of Biochemistry, Barcelona, Spain

754 Androgen deprivation therapy increased the risk of pulmonary embolism in patients with prostate cancer - from 24,464 patients, Taiwan National Health Insurance Research Database

By: Hong J.H., Lu Y-C., Huang C-Y., Pu Y-S.

National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan
Anti-androgen monotherapy versus GnRH agonists in men with non-metastatic prostate cancer

By: Thomsen F.B.¹, Bosco C.², Garmo H.², Adolfsson J.³, Hammar N.⁴, Stattin P.⁵, Van Hemelrijck M.²

¹Rigshospitalet Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, ²King’s College London, Dept. of Translational Oncology & Urology Research (TOUR), London, United Kingdom, ³Karolinska Institutet, Dept. of CLINTEC, Stockholm, Sweden, ⁴Karolinska Institutet, Dept. of Epidemiology, Stockholm, Sweden, ⁵Uppsala University Hospital, Dept. of Surgical Sciences, Uppsala, Sweden

Summary

A.S. Merseburger, Lübeck (DE)